The fact
The agreement aims to leverage generative AI capabilities to accelerate drug discovery and optimize clinical trials.
The partnership reflects a growing trend among major pharmaceutical groups to adopt AI technologies to reduce time-to-market and development costs.
27 sources — click a link to read an article on the topic:
Story timeline
Apr 14Novo Nordisk partners with OpenAI to accelerate pharmaceutical innovationthis article